Management Team and Advisors

Ken Mills
President and Chief Executive Officer

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

Olivier Danos, Ph.D.

Chief Scientific Officer

Dr. Olivier Danos is the Chief Scientific Officer for REGENXBIO. Prior to joining REGENXBIO, Dr. Danos was Senior Vice President, Cell and Gene Therapy at Biogen Inc. At Biogen, Dr. Danos led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering. Dr. Danos also co-founded and is an executive member of the board of directors of Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates for the treatment of Mucopolysaccharidosis Type IIIA.

 

Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Earlier in his career, Dr. Danos was Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation. Dr. Danos has directed research focused on gene therapy at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris.

Stephen Yoo, M.D.
Chief Medical Officer

Dr. Stephen Yoo is Chief Medical Officer at REGENXBIO. Prior to joining REGENXBIO, Dr. Yoo was Medical Science Director of Clinical Development at AstraZeneca and Group Director of Clinical Development at MedImmune, AstraZeneca's global biologics research and development arm. In these roles, he led the late-phase clinical project teams while providing strategic and operational leadership to physicians and scientists. In previous roles at MedImmune, he provided strategic clinical leadership for early phase programs. Earlier in his career, Dr. Yoo served as Associate Director of Clinical Development at Abbott Laboratories. Dr. Yoo holds an M.D. from the University of California, Los Angeles School of Medicine and a B.A. in molecular and cell biology from the University of California, Berkeley.

Vit Vasista
Chief Financial Officer

Vit Vasista is the Chief Financial Officer at REGENXBIO. Prior to joining REGENXBIO, Mr. Vasista served as Principal at PRTM Management Consultants, where he developed operational strategies for both private and public organizations, including the development of market entry strategies, innovative business models and operational improvements. Earlier in his career, Mr. Vasista served as Director, Business Development at Meso Scale Diagnostics, a privately held life sciences company. Mr. Vasista received an MBA from the Wharton School at the University of Pennsylvania, an M.S. in mechanical engineering from Stanford University and an S.B. in mechanical engineering from the Massachusetts Institute of Technology.

Faraz Ali

Chief Business Officer

Faraz Ali is Chief Business Officer at REGENXBIO. Prior to joining REGENXBIO, Mr. Ali was vice president, head of global commercial development and external affairs at bluebird bio where he led all commercial planning efforts, provided significant early input into bluebird bio’s portfolio strategy, and provided critical cross-functional leadership during the company’s initial growth phase by establishing new functions, processes and external relationships. Prior to bluebird bio, he held roles of increasing global commercial responsibility at Genzyme Corporation, including Head of U.S. Marketing and Strategic Planning for the rare disease business unit. Earlier in his career, Mr. Ali served in leadership roles at GE Healthcare. Mr. Ali holds an MBA with distinction from Harvard Business School and a B.S. in Electrical Engineering from Stanford University.
Patrick J. Christmas II, J.D.
Senior Vice President, General Counsel

Patrick J. Christmas II is Senior Vice President, General Counsel at REGENXBIO. He has over 15 years of life sciences leadership and public market experience.

 

Mr. Christmas has managed the legal, compliance, government affairs and business development functions at several biotech and pharmaceutical companies during times of significant growth and business success. Before joining REGENXBIO, he was Vice President, General Counsel and Secretary at Lumara Health (formerly KV Pharmaceutical Company - NYSE: KV.A) through its acquisition by AMAG Pharmaceuticals and Perrigo. Prior to Lumara Health, he was General Counsel and Secretary at the Wellstat Group of Companies and General Counsel at BioVeris Corporation (formerly NASDAQ: BIOV) until its acquisition by Roche. Prior to his extensive life sciences experience, Mr. Christmas was an Associate at Akin, Gump, a leading international law firm.

 

Mr. Christmas received his J.D. degree with honors from the University of Notre Dame and a B.A. in Economics from Boston College.

Laura Coruzzi, Ph.D., J.D.
Senior Vice President, Intellectual Property

Laura A. Coruzzi is the Senior Vice President of Intellectual Property at REGENXBIO. Prior to joining REGENXBIO, Ms. Coruzzi was a partner at Jones Day, preceded by Pennie & Edmonds, LLP where she counseled clients on patent strategies for biotech and pharmaceutical therapeutics and diagnostics. Her practice encompassed all aspects of patent law, including prosecution, litigation and appeals, in a variety of disciplines in the life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, other biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery.


Earlier in her career, Ms. Coruzzi was one of the first members of Pennie & Edmonds’ biotechnology group founded by S. Leslie Misrock, affectionately known as the "father of biotechnology patent law.” Most recently, she was a member of the team representing Myriad in Association for Molecular Pathology v. Myriad Genetics (U.S. Supreme Court 2013).


Ms. Coruzzi received her J.D. from Fordham University School of Law, her Ph.D., M.S. and B.S. in Biology from Fordham University, and completed a post-doctoral fellowship at the Mount Sinai School of Medicine before entering the practice of law.

Curran M. Simpson
Senior Vice President, Technical Operations

Curran M. Simpson is the Senior Vice President of Technical Operations at REGENXBIO. Prior to joining REGENXBIO, Mr. Simpson was the Head of North American Supply Chain and Interim Chief Operating Officer and Integration Lead at GlaxoSmithKline and the Human Genome Sciences division of GlaxoSmithKline. Mr. Simpson earlier served as Senior Vice President of Operations and Vice President of Manufacturing Operations at Human Genome Sciences.

 

Prior to Human Genome Sciences, Mr. Simpson was Director of Manufacturing Sciences at Biogen and Director of Engineering at Covance Biotechnology Services. Earlier in his career, Mr. Simpson served as Recovery Technology Coordinator, Worldwide and Pilot Plant Manager of the North America Division at Novo-Nordisk Biochem; Senior Research Engineer at Genentech; Senior Scientist, Development at Genencor; and Senior Chemist at Nalco Chemical Co.

 

Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemical engineering and chemistry from the Clarkson College of Technology.

Kimberly Sloan
Senior Vice President, Human Resources

Kimberly Sloan is the Senior Vice President, Human Resources at REGENXBIO. Prior to joining REGENXBIO, Ms. Sloan was the Vice President, Human Resources at Biocon/MTF. She was a valued member of the Compensation Committee and the Investment Committee. Ms. Sloan has extensive domestic and global experience in Human Resources.

 

Earlier in her career, Ms. Sloan held several senior leadership roles at Princeton Financial Systems and Dun & Bradstreet. She began her career with varied responsibilities in Human Resources at The Prudential Insurance Company and Central New Jersey Medical Group.

 

Ms. Sloan is a former Board of Trustees member for 501 (c) Services unemployment trust. She has a Bachelor’s degree in Psychology and a Master’s degree in Management and Industrial Relations from Rutgers University.

Sara Garon Berl, J.D.
Vice President, Law and Policy

Sara Garon Berl is the Vice President, Law and Policy at REGENXBIO. Prior to joining REGENXBIO, she was a Principal at FOXKISER LLP where she focused on developing strategies in a variety of legal and regulatory areas for FDA-regulated products. She previously served as an associate at Covington & Burling, where she focused on commercial litigation and arbitration in the areas of health law, intellectual property, securities and deceptive trade practices. Ms. Berl received a J.D. from Stanford University and an S.B. in mathematics from the Massachusetts Institute of Technology.

Niall Carolan, Ph.D.
Vice President, Manufacturing

Niall Carolan, Ph.D. is the Vice President of Manufacturing and Supply Chain at REGENXBIO. Prior to joining REGENXBIO, Mr. Carolan was the Director of Biopharmaceutical Technology at GlaxoSmithKline (GSK), leading a product technical oversight function and a process development lab function for GSK programs and as a CMO service provider. Before GSK, Mr. Carolan was Director of Manufacturing Sciences at Human Genome Sciences, with earlier roles in tech transfer, project management and supply chain. Earlier in his career, Mr. Carolan held roles in manufacturing management and global technology coordination at Novozymes, and in process engineering at Novo Nordisk in Denmark. Mr. Carolan holds a Ph.D. in bioprocessing and a B.Eng. in chemical engineering from the Queen's University, Belfast, Northern Ireland.

Jerome W. Jackson
Vice President, Information Technology

Jerome W. Jackson is the Vice President of Information Technology at REGENXBIO. Prior to joining REGENXBIO, Mr. Jackson served as the Director of Information Systems at Meso Scale Diagnostics, a privately held life sciences company where he was a member of the founding team and worked to establish and scale operations. Mr. Jackson holds an MBA and an M.S. in finance from the University of Maryland, Robert H. Smith School of Business and a B.S. in biochemistry from the University of Maryland, College Park.

Louis Licamele, Ph.D.

Vice President, Biometrics

Dr. Louis Licamele is the Vice President of Biometrics at REGENXBIO. Prior to joining REGENXBIO, Dr. Licamele was Vice President, Informatics at Vanda Pharmaceuticals Inc. overseeing the Biostatistics and Data Management functions and served as a member of the executive team. Dr. Licamele was responsible for setting up, optimizing and overseeing a wide range of functional units within Vanda spanning both clinical and commercial informatics while providing strategic and operational leadership relating to drug development for rare, orphan disorders. He helped setup the core informatics services when Vanda was founded in 2003.

 

Dr. Licamele holds a Ph.D. in Computer Science from the University of Maryland where his doctoral thesis was on computational methods for drug discovery. He also has a B.S. in both Biology and Computer Science from Georgetown University and a M.S. in Computer Science from the University of Maryland.

Lynne Fahey McGrath, Ph.D.
Vice President, Regulatory Affairs

Lynne Fahey McGrath, Ph.D., is the Vice President of Regulatory Affairs at REGENXBIO. Prior to joining REGENXBIO, Ms. McGrath was Global Head of Regulatory Affairs at Novartis Consumer Heath where she led a team of 250 regulatory and CMC associates in 50 countries, managing more than 10,000 product licenses. She played a key R&D role in the creation of the Novartis - GlaxoSmithKline joint venture. Previously, Ms. McGrath spent 10 years at Novartis Oncology managing global strategy for multiple development teams and as U.S. Head of Regulatory Affairs, where she directed the strategy for accelerated approval of multiple drugs including those for rare diseases worldwide.

 

Prior to Novartis, Ms. McGrath worked at Pharmacia as global regulatory lead in oncology, most notably successfully registering Celebrex in the EU for a rare genetic disease. In addition, she worked at Schering Plough for seven years, both in regulatory affairs and in toxicology, and at Hoechst for eight years, managing product safety and risk assessment.

 

Ms. McGrath holds a Ph.D. and an M.P.H. in public health from the University of Medicine and Dentistry of NJ - Robert Wood Johnson Medical School and a B.S. in biology and chemistry from the University of Connecticut.

Rickey Reinhardt, M.D., Ph.D.
Vice President, Clinical Research & Development

Rickey Reinhardt is the Vice President of Clinical Research & Development at REGENXBIO. Prior to joining REGENXBIO, Dr. Reinhardt worked for GlaxoSmithKline (GSK) in the Rare Disease Unit as Vice President, Translational Medicine and Clinical Development. Prior to GSK, he worked for Covance as Vice President of Global Molecule Development, Novo Nordisk as Executive Director of Clinical Pharmacology, Clinical Research and Medical Affairs (Metabolic Diseases), and Merck as Associate Director of Clinical Pharmacology. His experience has included preclinical, clinical, regulatory, and medico-marketing strategy and hands on experience with all aspects of the clinical trial process for clinical pharmacology, registration, and post-marketing trials.

 

Dr. Reinhardt obtained his Bachelor’s Degree in Biochemistry from the University of California (UCLA), and Ph.D. and M.D. from Louisiana State University.

Réka Shinkle
Vice President, Commercial & Portfolio Planning

Réka Shinkle is the Vice President of Commercial and Portfolio Planning at REGENXBIO. Prior to joining REGENXBIO, she served as Head, Early Cardiovascular and Metabolic Disease in AstraZeneca's Global Product and Portfolio Strategies group. Previously, Ms. Shinkle held roles of increasing responsibility in new product planning, global strategy marketing and portfolio planning at MedImmune, the fully integrated biologics subsidiary of AstraZenenca. These roles spanned therapeutic areas, and involved partnering with research and development colleagues to progress the biologics pipeline as well as building capabilities. Ms. Shinkle also held sales and marketing positions at Eli Lilly & Company, including global-launch planning, market research and brand strategy. Ms. Shinkle received an MBA from the University of Michigan and a B.S. in chemistry from Yale University.

Rebecca Simamora

Vice President, Clinical Operations

Rebecca Simamora is the Vice President of Clinical Operations at REGENXBIO. Prior to joining REGENXBIO, Ms. Simamora was a Senior Director, Clinical Operations Head, Cardiovascular and Metabolic Disease at MedImmune, a subsidiary of AstraZeneca, and built the clinical operations team to deliver on the CVMD biologics portfolio. Prior to MedImmune, Ms. Simamora was the Director of Clinical Affairs at Fujirebio Diagnostics, Inc. where she spent three years managing a clinical operations team and enhancing operational efficiency. Ms. Simamora also held positions earlier in her career at Schering-Plough, Wyeth and Shire. Ms. Simamora received a Bachelor of Science in Chemistry from University of Pittsburgh.

Sarah Thomas

Vice President, Quality

Sarah Thomas is the Vice President of Quality at REGENXBIO. Ms. Thomas joined REGENXBIO with over 28 years’ experience in pharmaceutical and biotech Quality, including serving as VP, Quality at Human Genome Sciences and Quality leadership positions at GSK, Cell Genesys and SEQUUS. She has experience working with products at all phases of development, from early clinical phases to commercial distribution. She has led Quality teams through multiple product approvals. Ms. Thomas received an MBA from George Washington University and a BS in chemistry from Butler University.

Sherri Van Everen, Pharm.D.

Vice President, Medical Affairs

Sherri Van Everen is the Vice President of Medical Affairs at REGENXBIO. Prior to joining REGENXBIO, Dr. Van Everen worked for Avalanche Biotechnologies as Executive Director of Scientific Collaborations, Translational Medicine, leading all Medical Affairs activities. Prior to that, she worked for Genentech and Eli Lilly and Company. Her experience has included medical affairs roles in outcomes research, health economics, field medical affairs, publications and congress strategy. Her therapeutic experience includes cell and gene therapy, Retina, Ophthalmology and Critical Care.

 

Dr. Van Everen obtained her Bachelor’s Degree in Biomedical Science from Texas A&M University and Pharm.D. from the University of Texas at Austin.

Andrew Yost

Vice President, Corporate Development

Andrew Yost is the Vice President of Corporate Development at REGENXBIO. Prior to joining REGENXBIO, he served in the Healthcare Investment Banking team at JP Morgan, where he advised on more than $25 billion in transactions across the life sciences sector. He began his career at PRTM Management Consultants, where he designed and implemented strategic and operational solutions for a variety of life science companies, from start-ups to the Fortune 20. Mr. Yost holds an MBA with Honors from the University of Chicago Booth School of Business and a B.S. in Biological Engineering from Cornell University.
James M. Wilson, M.D., Ph.D.
Scientific Founder and Special Advisor

Dr. Jim Wilson is the Scientific Founder of and Special Advisor to REGENXBIO. He is also professor and director of the Gene Therapy Program in the Department of Medicine at the University of Pennsylvania. Dr. Wilson has dedicated his career to gene therapy and much of his research has focused on the development of AAV vectors as vehicles for gene delivery. Following his residency in internal medicine at the Harvard-affiliated Massachusetts General Hospital and a postdoctoral fellowship at the Massachusetts Institute of Technology, Dr. Wilson took his first faculty position and began his studies in gene therapy at the University of Michigan. Dr. Wilson holds an M.D. and a Ph.D. from the University of Michigan and a B.S. in chemistry from Albion College.